Clinical Trial

Spatiotemporal Associations Between the COVID-19 Pandemic and Cancer Diagnoses in Bavaria

Study acronym: PanSCan
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The COVID-19 pandemic has placed a significant strain on healthcare systems worldwide and has also impacted the diagnosis and treatment of cancer. In Germany, there was a notable decline in cancer diagnoses during the pandemic, partly due to delays in early detection and limited access to medical treatments. This study examines how the number of cancer cases in Bavaria changed before and during the pandemic, taking various factors into account, such as the socioeconomic status of different regions, the age of affected individuals, and the severity of the pandemic in each region. We aim to determine whether certain regions or specific types of tumors experienced greater declines in diagnoses, particularly for cancers with regular screening programs. The study seeks to provide a better understanding of how different social and geographical conditions influenced cancer diagnoses during the pandemic. These insights could help improve future preparedness for health crises like the pandemic and ensure that cancer treatment continues to function effectively even in times of crisis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-05.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-01-05
Trial Details
NCT Number NCT07008560
Lead Sponsor Bavarian Cancer Registry
Collaborators: Ludwig-Maximilians - University of Munich
Conditions Cancer
Enrollment 438,000 participants
Start Date 2025-09-03
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-06